Drug Trial Radar · NCT07734415
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
400
Planned (sponsor's estimate)
Start
Jun 5, 2026
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Inmagene LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
Conditions
- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
Interventions
IMG-007Drug
Participants will receive IMG-007 subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitisTime frame: Baseline, Week 44
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
Inmagene Site 1
Lancaster, California
Inmagene Site 23
Los Angeles, California
Inmagene Site 19
Ocala, Florida
Inmagene Site 4
Tampa, Florida
Inmagene Site 2
Rolling Meadows, Illinois
Inmagene Site 6
Kew Gardens, New York
Inmagene Site 21
New York, New York
Inmagene Site 11
Woodbury, New York
Inmagene Site 20
Charlotte, North Carolina
Inmagene Site 10
Fargo, North Dakota
Inmagene Site 9
Columbus, Ohio
Inmagene Site 5
Mayfield Heights, Ohio
Inmagene Site 3
Portland, Oregon
Inmagene Site 12
Anderson, South Carolina
Inmagene Site 8
Southlake, Texas
Inmagene Site 7
Burien, Washington
Inmagene Site 15
Surrey, British Columbia, Canada
Inmagene Site 22
Vancouver, British Columbia, Canada
Inmagene Site 17
Greater Sudbury, Ontario, Canada
Inmagene Site 13
Mississauga, Ontario, Canada
Inmagene Site 18
North Bay, Ontario, Canada
Inmagene Site 14
Montreal, Quebec, Canada
Inmagene Site 16
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.